Sam Possemiers

Company: MRM Health

Job title: Chief Executive Officer

Seminars:

Clinical & Mechanistic Insights From Phase 2a Studies with Optimized Consortia Therapeutic MH002 in Ulcerative Colitis & Pouchitis as Basis for Future Pipeline Development 8:30 am

MH002, a 6-strain consortia therapeutic designed, optimized and manufactured through MRM Health’s CORAL® technology, is the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis Receive integrated insight on the translation of the mechanism of action of MH002 in activity in both Ulcerative Colitis and Pouchitis patients Explore how insights from different…Read more

day: Conference Day One